{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:32:18Z","timestamp":1778427138230,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:00:00Z","timestamp":1713657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:00:00Z","timestamp":1713657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02978-z","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T14:01:21Z","timestamp":1713708081000},"page":"871-876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Equivalent thrombotic risk with Warfarin, Dabigatran, or Enoxaparin after failure of initial direct oral anticoagulation (DOAC) therapy"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-6282","authenticated-orcid":false,"given":"Margaret","family":"Shyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anya","family":"Srikureja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Gregorian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Srisuwananukorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Naymagon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,21]]},"reference":[{"key":"2978_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.thromres.2022.11.016","volume":"222","author":"AGG Turpie","year":"2023","unstructured":"Turpie AGG, Farjat AE, Haas S, Ageno W, Weitz JI, Goldhaber SZ et al (2023) 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. Thromb Res 222:31\u201339. https:\/\/doi.org\/10.1016\/j.thromres.2022.11.016","journal-title":"Thromb Res"},{"issue":"26","key":"2978_CR2","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS et al (2010) Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510. https:\/\/doi.org\/10.1056\/NEJMoa1007903","journal-title":"N Engl J Med"},{"issue":"9","key":"2978_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Oral apixaban for the treatment of Acute venous thromboembolism. N Engl J Med 369(9):799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"},{"issue":"11","key":"2978_CR4","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/jth.15491","volume":"19","author":"F Khan","year":"2021","unstructured":"Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI et al (2021) Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta\u2010analysis. J Thromb Haemost 19(11):2801\u20132813. https:\/\/doi.org\/10.1111\/jth.15491","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2978_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jth.14398","volume":"17","author":"MAT Elsebaie","year":"2019","unstructured":"Elsebaie MAT, Van Es N, Langston A, B\u00fcller HR, Gaddh M (2019) Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost 17(4):645\u2013656. https:\/\/doi.org\/10.1111\/jth.14398","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2978_CR6","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/jth.12955","volume":"13","author":"S Schulman","year":"2015","unstructured":"Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, De Sancho M et al (2015) Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost 13(6):1010\u20131018. https:\/\/doi.org\/10.1111\/jth.12955","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2978_CR7","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al (2018) Comparison of an oral factor xa inhibitor with low Molecular Weight Heparin in patients with Cancer with venous thromboembolism: results of a Randomized Trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023. https:\/\/doi.org\/10.1200\/jco.2018.78.8034","journal-title":"J Clin Oncol"},{"issue":"17","key":"2978_CR8","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/nejmoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM et al (2020) Apixaban for the treatment of venous Thromboembolism Associated with Cancer. N Engl J Med 382(17):1599\u20131607. https:\/\/doi.org\/10.1056\/nejmoa1915103","journal-title":"N Engl J Med"},{"issue":"3","key":"2978_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11239-020-02042-6","volume":"49","author":"G Mcilroy","year":"2020","unstructured":"Mcilroy G, Smith N, Lokare A, Beale K, Kartsios C (2020) Management of venous thromboembolism in patients experiencing direct oral anticoagulant treatment failure: a single-center review of practice and outcomes. J Thromb Thrombolysis 49(3):441\u2013445. https:\/\/doi.org\/10.1007\/s11239-020-02042-6","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2978_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"25","key":"2978_CR11","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1182\/blood-2017-03-742304","volume":"129","author":"S Schulman","year":"2017","unstructured":"Schulman S (2017) How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood 129(25):3285\u20133293. https:\/\/doi.org\/10.1182\/blood-2017-03-742304","journal-title":"Blood"},{"issue":"7","key":"2978_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/circulationaha.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P et al (2014) Treatment of Acute venous thromboembolism with Dabigatran or Warfarin and Pooled Analysis. Circulation 129(7):764\u2013772. https:\/\/doi.org\/10.1161\/circulationaha.113.004450","journal-title":"Circulation"},{"issue":"5","key":"2978_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","volume":"7","author":"M Carrier","year":"2009","unstructured":"Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY (2009) Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 7(5):760\u2013765. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03326.x","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2978_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","volume":"134","author":"R Ihaddadene","year":"2014","unstructured":"Ihaddadene R, Gal GL, Delluc A, Carrier M (2014) Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res 134(1):93\u201395. https:\/\/doi.org\/10.1016\/j.thromres.2014.04.028","journal-title":"Thromb Res"},{"issue":"4","key":"2978_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Nisio MD, Hicks LK, Khorana AA et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442","journal-title":"Blood Adv"},{"issue":"9","key":"2978_CR16","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jth.12338","volume":"11","author":"M Carrier","year":"2013","unstructured":"Carrier M, Khorana AA, Zwicker JI, Noble S, Lee AYY (2013) Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 11(9):1760\u20131765. https:\/\/doi.org\/10.1111\/jth.12338","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2978_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","volume":"3","author":"L Gervaso","year":"2021","unstructured":"Gervaso L, Dave H, Khorana AA (2021) Venous and arterial thromboembolism in patients with Cancer: JACC CardioOncology State-of-the-art review. JACC CardioOncol 3(2):173\u2013190. https:\/\/doi.org\/10.1016\/j.jaccao.2021.03.001","journal-title":"JACC CardioOncol"},{"issue":"5","key":"2978_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/jco.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2020) Venous thromboembolism prophylaxis and treatment in patients with Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 38(5):496\u2013520. https:\/\/doi.org\/10.1200\/jco.19.01461","journal-title":"J Clin Oncol"},{"issue":"1","key":"2978_CR19","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1002\/onco.13584","volume":"26","author":"C O\u2019Connell","year":"2021","unstructured":"O\u2019Connell C, Escalante CP, Goldhaber SZ, Mcbane R, Connors JM, Raskob GE (2021) Treatment of Cancer-Associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. Oncologist 26(1):e8\u2013e16. https:\/\/doi.org\/10.1002\/onco.13584","journal-title":"Oncologist"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02978-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02978-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02978-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:14:43Z","timestamp":1720516483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02978-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,21]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["2978"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02978-z","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,21]]},"assertion":[{"value":"2 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Douglas Tremblay receives contracted research funding paid to his institution from CTI Biopharma, Astellas Pharma and Gilead and consulting fees from CTI Biopharma, Novartis, AbbVie, Sierra Oncology, GSK and Cogent Biosciences. The authors have no other conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and Declarations"}}]}}